Cholangiocarcinoma Market, By Cancer Type, By Therapy Type, By Route of Administration, By Distribution Channel, and By Region

Description

Cholangiocarcinoma Market is estimated to be valued at USD 618.3 Mn in 2025 and is expected to reach USD 2,334.4 Mn by 2032, growing at a compound annual growth rate (CAGR) of 20.9% from 2025 to 2032.

Report Coverage		Report Details
Base Year:	2024	Market Size in 2025:	USD 618.3 Mn
Historical Data for:	2020 To 2024	Forecast Period:	2025 To 2032
Forecast Period 2025 to 2032 CAGR:	20.90%	2032 Value Projection:	USD 2,334.4 Mn

Bile duct cancer is also called as cholangiocarcinoma. Cholangiocarcinoma is a form of cancer in which epithelial cells are mutated, which means the cells show characters of epithelial differentiation in the bile duct. The bile duct carries a fluid called bile, which is secreted in the liver and stored in the gall bladder. The essential function of bile is to breakdown the fats during digestion. Signs of bile duct cancer include jaundice and pain in the abdomen. There are two types of bile duct cancer intrahepatic bile duct cancer and extrahepatic bile duct cancer. Intrahepatic bile duct cancer occurs in the parts of the bile ducts within the liver. Extrahepatic bile duct cancer is a rare cancer that forms in the bile ducts outside the liver.

Market Dynamics

Key players operating in the global cholangiocarcinoma market are focusing on adoption of inorganic growth strategies such as collaborations, which are expected to drive the market growth during the forecast period. For instance, In March 2021, QED Therapeutics collaborated with Helsinn Group, is a privately-owned Swiss Pharma Company. The collaboration intends to co-develop and commercialize Infigratinib, an oral FGFR1-3 selective inhibitor, for patients dealing with cholangiocarcinoma (bile duct cancer). Moreover, In February 2019, Imbrium Therapeutics L.P., in collaboration with Mundipharma EDO GmbH, a part of the Mundipharma-network, announced that the U.S. Food and Drug Administration (FDA) granted orphan drug designation (ODD) to its investigational drug etoposide toniribate, a novel topoisomerase II inhibitor, for the treatment of relapsed refractory biliary tract cancer.

Key features of the study:

This report provides an in-depth analysis of the global cholangiocarcinoma market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period 2025-2032, considering 2024 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global cholangiocarcinoma market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, strategies
Key companies covered as a part of this study include Incyte Corporation, Eisai Co., Ltd., QED Therapeutics, Inc., Agios Pharmaceuticals, Inc., RenovoRx, Ability Pharmaceuticals, Imbrium Therapeutics L.P., and Delcath Systems Inc.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global cholangiocarcinoma market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have an ease in decision-making through various strategy matrices used in analyzing the global cholangiocarcinoma market

Detailed Segmentation:

Global Cholangiocarcinoma Market, By Treatment Type:
- Chemotherapy
- Gemcitabine
- Cisplatin
- Oxaliplatin
- Capecitabine
- 5 fluorouracil (5-FU)
- Targeted Therapy
- Pemigatinib
- Infigratinib (Phase 3)
- Ivosidenib (Phase 3)
- Immunotherapy
- Pembrolizumab (Phase 3)
- Others
Global Cholangiocarcinoma Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Global Cholangiocarcinoma Market, By Region:
- North America
- Latin America
- Europe
- Asia Pacific
- Middle East
- Africa
Company Profiles
- Incyte Corporation
- Eisai Co., Ltd.
- QED Therapeutics, Inc.
- Agios Pharmaceuticals, Inc.
- RenovoRx
- Ability Pharmaceuticals
- Imbrium Therapeutics L.P.
- Delcath Systems, Inc.

Product Code: CMI4435

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snippet, By Cancer Type
- Market Snippet, By Therapy Type
- Market Snippet, By Route of Administration
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
Drivers
Restraints
Opportunities
Recent Product Launches/Approvals
Recent Trends
Mergers, Acquisitions, and Collaborations
Regulatory Scenario
Key Developments
PEST Analysis
PORTER's Analysis

4. Global Cholangiocarcinoma Market - COVID-19 Impact Analysis

Economic Impact
COVID-19 Epidemiology
Impact on Supply and Demand

5. Global Cholangiocarcinoma Market, By Cancer Type, 2020 - 2032, (US$ Mn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Extrahepatic Cholangiocarcinoma
Perihilar
Distal
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (US$ Mn)
- Segment Trends
Intrahepatic Cholangiocarcinoma
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (US$ Mn)
- Segment Trends

6. Global Cholangiocarcinoma Market, By Therapy Type, 2020 - 2032, (US$ Mn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Targeted Drug Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (US$ Mn)
- Segment Trends
Pemigatinib
Ivosidenib
Futibatinib
Infigratinib
Chemotherapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (US$ Mn)
- Segment Trends
5- fluorouracil
Gemcitabine
Cisplatin
Capecitabine
Oxaliplatin
Immunotherapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (US$ Mn)
- Segment Trends
Pembrolizumab
Others (Late phase pipeline drugs)
Others (Pain Medications and others)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (US$ Mn)
- Segment Trends

7. Global Cholangiocarcinoma Market, By Route of Administration, 2020 - 2032, (US$ Mn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Oral
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Subcutaneous
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Intravenous
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends

8. Global Cholangiocarcinoma Market, By Distribution Channel, 2020 - 2032, (US$ Mn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (US$ Mn)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (US$ Mn)
E-commerce
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (US$ Mn)

9. Global Cholangiocarcinoma Market, By Region, 2020 - 2032, (US$ Mn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2020 -2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Therapy Type, 2020 -2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (US$ Mn)
  - U.S.
  - Canada
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2020 -2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Therapy Type, 2020 -2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (US$ Mn)
  - U.K.
  - Germany
  - Italy
  - France
  - Spain
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2020 -2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Therapy Type, 2020 -2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (US$ Mn)
  - China
  - India
  - Japan
  - ASEAN
  - Australia
  - South Korea
  - Rest of Asia Pacific
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2020 -2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Therapy Type, 2020 -2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (US$ Mn)
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2020 -2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Therapy Type, 2020 -2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (US$ Mn)
  - GCC
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2020 -2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Therapy Type, 2020 -2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (US$ Mn)
- Market Size and Forecast, and By Y-o-Y Growth, By Region, 2020 - 2032, (US$ Mn)
North Africa
Central Africa
South Africa

10. Competitive Landscape

Company Profiles
- BridgeBio Inc.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Sanofi
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Eisai Co., Ltd.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Eli Lilly and Company
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Teva Pharmaceutical Industries Ltd.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Intas Pharmaceuticals Ltd.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Fresenius SE & Co. KGaA
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Sun Pharmaceutical Industries Ltd.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Hikma Pharmaceuticals PLC
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Incyte
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- TRISALUS LIFE SCIENCES, INC.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- GENFIT
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Johnson & Johnson Private Limited
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Bliss Biopharmaceutical
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Novartis AG
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- LES LABORATOIRES SERVIER
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- F.Hoffmann-La Roche Ltd
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Mylan N.V. (Viatris.Inc)
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- AstraZeneca
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Compass Therapeutics, Inc
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Otsuka Holdings Co., Ltd.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Senhwa Biosciences, Inc.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
  - Analysts' Views

11. Section

References
Research Methodology
About us and Sales Contact